Latest Period
Q2 2026
Security Snapshot
Marker Therapeutics, Inc. - Common Stock, par value $0.001 per share (MRKR) Institutional Ownership
CUSIP: 57055L206
13F Institutional Holders and Ownership History from Q1 2023 to Q2 2026
Institutions Reporting
35
Shares (Excl. Options)
3,970,010
Price
$1.47
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- MRKR on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 3,970,010
- Total 13F value
- $5,835,886
- Portfolio coverage rank
- 0%
- Share change
- +67,137
- Value change
- +$113,884
- Number of holders
- 35
- Shares outstanding
- 16,869,505
- SEC-reported price per share
- $1.22
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- MRKR - Marker Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 57055L206.
- 35 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 35 to 35 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $5,073,369 to $5,835,886.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 35 institutions filings for Q2 2026.
Security key
57055L206
Latest holder period
Q2 2026
13F holders
35
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
MRKR full holder history
Marker Therapeutics, Inc. SEC filings
Marker Therapeutics, Inc. company facts
Marker Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 57055L206:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
MRKR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| New Enterprise Associates 16, L.P. | 9.9% | -21% | $1,703,483 | +$45,291 | 1,670,081 | +2.7% | New Enterprise Associates 16, L.P. | 13 Nov 2025 |
| Alyeska Investment Group, L.P. | 9.9% | -0.9% | $1,143,378 | +$188,600 | 1,280,952 | +20% | Alyeska Investment Group, L.P. | 30 Sep 2025 |
| Blue Owl Capital Holdings LP | 10% | +96% | $1,431,356 | +$727,459 | 1,127,052 | +103% | Blue Owl Capital Holdings LP | 31 Mar 2025 |
As of 30 Jun 2026, 35 institutional investors reported holding 3,970,010 shares of Marker Therapeutics, Inc. - Common Stock, par value $0.001 per share (MRKR). This represents 24% of the company’s total 16,869,505 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
24%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 9.6% | 1,625,678 | 0% | 0.15% | $2,389,747 |
| Blue Owl Capital Holdings LP | 3.3% | 554,250 | 0% | 0.12% | $814,748 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 426,169 | +9.5% | 0% | $626,468 |
| Aisling Capital Management LP | 1.9% | 325,370 | 0% | 0.1% | $478,293 |
| RENAISSANCE TECHNOLOGIES LLC | 1.5% | 249,423 | +42% | 0% | $366,652 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.83% | 139,816 | -13% | 0% | $205,558 |
| OSAIC HOLDINGS, INC. | 0.67% | 112,649 | +21% | 0% | $165,590 |
| VANGUARD FIDUCIARY TRUST CO | 0.52% | 87,269 | 0% | 0% | $128,285 |
| LPL Financial LLC | 0.49% | 83,147 | +0.12% | 0% | $122,226 |
| Concurrent Investment Advisors, LLC | 0.4% | 67,963 | 0% | $99,906 | |
| TWO SIGMA INVESTMENTS, LP | 0.36% | 60,201 | -1.3% | 0% | $88,495 |
| XTX Topco Ltd | 0.27% | 45,357 | -29% | 0% | $66,675 |
| NORTHERN TRUST CORP | 0.21% | 34,629 | +33% | 0% | $50,905 |
| CITADEL ADVISORS LLC | 0.19% | 32,517 | 0% | $47,800 | |
| STATE STREET CORP | 0.12% | 20,948 | 0% | 0% | $30,794 |
| Invst, LLC | 0.11% | 18,000 | -38% | 0% | $26,460 |
| Creative Planning | 0.1% | 17,312 | 0% | 0% | $25,449 |
| JANE STREET GROUP, LLC | 0.1% | 16,832 | -54% | 0% | $24,743 |
| Ashton Thomas Private Wealth, LLC | 0.1% | 16,400 | 0% | 0% | $24,108 |
| Virtu Financial LLC | 0.07% | 11,574 | 0% | $17,000 | |
| FIFTH THIRD BANCORP | 0.06% | 10,000 | 0% | 0% | $14,700 |
| UBS Group AG | 0.05% | 8,150 | -75% | 0% | $11,981 |
| Vanguard Global Advisers, LLC | 0.01% | 2,512 | 0% | 0% | $3,693 |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | 0.01% | 2,000 | 0% | 0% | $2,900 |
| Tower Research Capital LLC (TRC) | 0% | 810 | -74% | 0% | $1,191 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
14
Latest
Q2 2026
Rows shown
1-14 of 14
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 3,970,010 | $5,835,886 | +$113,884 | $1.47 | 35 |
| 2026 Q1 | 3,902,873 | $5,073,369 | -$405,717 | $1.30 | 35 |
| 2025 Q4 | 4,044,475 | $6,027,366 | +$898,868 | $1.49 | 36 |
| 2025 Q3 | 3,455,371 | $3,085,979 | -$181,920 | $0.89 | 32 |
| 2025 Q2 | 3,410,487 | $5,218,067 | -$775,167 | $1.53 | 31 |
| 2025 Q1 | 4,023,536 | $4,948,972 | +$278,481 | $1.23 | 31 |
| 2024 Q4 | 3,484,395 | $10,763,745 | +$4,748,926 | $3.11 | 31 |
| 2024 Q3 | 1,936,917 | $5,462,150 | -$201,922 | $2.82 | 27 |
| 2024 Q2 | 1,938,345 | $10,524,473 | +$162,842 | $5.43 | 26 |
| 2024 Q1 | 1,911,504 | $8,219,717 | +$19,050 | $4.30 | 26 |
| 2023 Q4 | 1,906,940 | $10,488,483 | +$197,065 | $5.50 | 24 |
| 2023 Q3 | 1,871,217 | $8,502,131 | +$261,000 | $4.54 | 26 |
| 2023 Q2 | 1,824,779 | $5,655,903 | +$1,085,797 | $3.10 | 27 |
| 2023 Q1 | 1,624,962 | $1,154,593 | +$1,154,593 | $0.71 | 26 |